No Picture
News

STAT Plus: Pharmalittle: FDA is willing to fast-track a Covid-19 vaccine; most Americans worry politics drives vaccine approval process

Seventy-eight percent of Americans worry the Covid-19 vaccine approval process is being driven more by politics than science, according to a new survey. […]

No Picture
News

Ashvattha Therapeutics Subsidiary Orpheris Enrolls First Patients in Phase 2 PRANA Clinical Study Evaluating OP-101 for Severe COVID-19

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Orpheris, a wholly-owned subsidiary of Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in inflammatory, oncology and ocular… […]

No Picture
News

Eiger Announces Peginterferon Lambda – Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study in Late Breaker Session at The Digital International Liver Congress(TM) 2020

– 96% of Patients Achieve Primary Endpoint of > 2 Log Decline in HDV RNA- 58% of Patients Below Limit of Quantitation or Undetectable at Week 24

PALO ALTO, Calif., Aug. 31, 2020 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused o… […]

No Picture
News

Addario Lung Cancer Medical Institute and Biodesix Initiate Prospective Study to Predict Overall Survival Using Checkpoint Immunotherapy for Front-Line Lung Cancer in Patients with High PDL1 Expression

SAN CARLOS, Calif. & BOULDER, Colo.–(BUSINESS WIRE)–Addario Lung Cancer Medical Institute (ALCMI) and Biodesix, Inc. today announced they will begin an observational study to prospectively evaluate the clinical utility of biomarkers, including th… […]

No Picture
News

Unfazed by slow rollout, Nestlé buys out Aimmune and its peanut allergy med for $2.6B

After steadily tightening its grip on Aimmune Therapeutics over the past four years, Nestlé is swooping in to take full control.
The Swiss food and drink conglomerate is anting up $2.6 billion to acquire Aimmune at $34.5 per share, 174% more than its c… […]